Pricing Log in Create free account

Cingulate Inc. (CING) vs Spero Therapeutics, Inc. (SPRO)

Cingulate Inc. and Spero Therapeutics, Inc. are both Biotechnology companies. Cingulate Inc. and Spero Therapeutics, Inc. are of similar size ($65.8M and $63.8M). Cingulate Inc. has negative trailing earnings, so its P/E is not meaningful; Spero Therapeutics, Inc. trades at 7.9×. Across the 9 metrics below, Spero Therapeutics, Inc. leads on 9 and Cingulate Inc. on 0.

Valuation

Metric CING SPRO Biotechnology median
P/E n/m 7.86 8.50
P/S n/m 1.04 9.71
P/B 2.43 1.44 2.13
Price to free cash flow n/m 3.26 20.82
EV/EBITDA n/m 2.16 0.64
EV/Sales n/m 0.21 9.21
Earnings yield (82.91%) 12.73% (33.15%)
Free cash flow yield (36.67%) 30.65% (25.50%)

Profitability

Metric CING SPRO Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (198.74%) 19.17% (56.36%)
Return on assets (123.76%) 12.85% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CING SPRO Biotechnology median
Revenue growth (TTM) — 37.24% 6.02%
EPS growth (last fiscal year) 56.47% 111.81% 30.26%
Revenue growth, 5-year CAGR — 48.25% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CING SPRO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.50 6.12 4.72
Net debt to EBITDA 0.51 (6.38) 0.96

Dividend

Metric CING SPRO Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CING SPRO Biotechnology median
Market cap 63.84m 65.80m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack